GlassScriptPhysician profile
Tara Parvathaneni
NPI 1063064012
$3,337.43
in general payments reported to CMS, 2019-2025
14 companies · $640 in 2025
The $640 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,137 · 2022: $735 · 2023: $257 · 2024: $569 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $787.50 | 2021-2023 | Reveal Linq |
| Biotronik INC. | $667.89 | 2021-2024 | Amvia Edge |
| Astrazeneca Pharmaceuticals LP | $533.20 | 2023-2025 | Fasenra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.79 | 2021 | |
| Kyowa Kirin, INC. | $139.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $129.39 | 2025 | |
| Amgen INC. | $128.10 | 2024 | Repatha |
| Otsuka America Pharmaceutical, INC. | $124.97 | 2023 | Rexulti |
| Genzyme Corporation | $124.84 | 2022 | |
| Neurocrine Biosciences, INC. | $123.17 | 2024 | Ingrezza |
| Atricure, INC. | $114.69 | 2021 | |
| Dexcom, INC. | $104.57 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Lilly USA, LLC | $104.12 | 2024 | Mounjaro |
| Jazz Pharmaceuticals INC. | $98.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Parvathaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.